Superior Efficacy and Improved Renal and Bone Safety After Switching From a Tenofovir Disoproxil Fumarate (TDF)- to a Tenofovir Alafenamide (TAF)-based Regimen Through 96 Weeks of Treatment.
| Author | |
|---|---|
| Abstract |
:
We previously demonstrated superior efficacy and safety advantages in HIV-infected, virologically suppressed adults switched to a regimen containing tenofovir alafenamide (TAF) as compared with those remaining on a tenofovir disoproxil fumarate (TDF) regimen through week 48. We now report longer-term data through week 96. |
| Year of Publication |
:
2018
|
| Journal |
:
AIDS research and human retroviruses
|
| Date Published |
:
2018
|
| ISSN Number |
:
0889-2229
|
| URL |
:
http://dx.doi.org/10.1089/AID.2017.0203
|
| DOI |
:
10.1089/AID.2017.0203
|
| Short Title |
:
AIDS Res Hum Retroviruses
|
| Download citation |
